Hos 2461 patienter behandlet med telithromycin i fase III kliniske forsøg samt igennem post - marketing erfaring blev følgende bivirkninger, der muligvis eller sandsynligvis kunne relateres til telithromycin, rapporteret.
In 2461 patients treated by Ketek in phase III clinical trials, and during postmarketing experience, the following undesirable effects possibly or probably related to telithromycin have been reported.